Sign In
Buy COIHY
Croda International Earnings Calls
| Release date | Feb 24, 2026 |
| EPS estimate | - |
| EPS actual | $0.0037 |
| Revenue estimate | 548.602M |
| Revenue actual | 1.128B |
| Revenue Surprise | 105.63% |
| Release date | Jul 29, 2025 |
| EPS estimate | - |
| EPS actual | $0.298 |
| Revenue estimate | - |
| Revenue actual | 1.166B |
| Release date | Apr 24, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 25, 2025 |
| EPS estimate | - |
| EPS actual | $0.353 |
| Revenue estimate | 563.682M |
| Revenue actual | 1.016B |
| Revenue Surprise | 80.27% |
Last 4 Quarters for Croda International
Below you can see how COIHY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $20.60 |
| EPS estimate | - |
| EPS actual | $0.353 |
| Date | Price |
|---|---|
| Feb 19, 2025 | $20.08 |
| Feb 20, 2025 | $20.01 |
| Feb 21, 2025 | $20.16 |
| Feb 24, 2025 | $20.12 |
| Feb 25, 2025 | $20.60 |
| Feb 26, 2025 | $21.11 |
| Feb 27, 2025 | $20.81 |
| Feb 28, 2025 | $21.09 |
| Mar 03, 2025 | $20.68 |
| 4 days before | 2.59% |
| 4 days after | 0.388% |
| On release day | 2.02% |
| Change in period | 2.99% |
| Release date | Apr 24, 2025 |
| Price on release | $20.02 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 17, 2025 | $17.93 |
| Apr 21, 2025 | $17.93 |
| Apr 22, 2025 | $18.44 |
| Apr 23, 2025 | $19.61 |
| Apr 24, 2025 | $20.02 |
| Apr 25, 2025 | $19.86 |
| Apr 28, 2025 | $20.05 |
| Apr 29, 2025 | $20.33 |
| Apr 30, 2025 | $19.78 |
| 4 days before | 11.66% |
| 4 days after | -1.20% |
| On release day | -0.549% |
| Change in period | 10.32% |
| Release date | Jul 29, 2025 |
| Price on release | $17.35 |
| EPS estimate | - |
| EPS actual | $0.298 |
| Date | Price |
|---|---|
| Jul 23, 2025 | $19.65 |
| Jul 24, 2025 | $19.39 |
| Jul 25, 2025 | $19.50 |
| Jul 28, 2025 | $19.28 |
| Jul 29, 2025 | $17.35 |
| Jul 30, 2025 | $16.77 |
| Jul 31, 2025 | $17.10 |
| Aug 01, 2025 | $17.38 |
| Aug 04, 2025 | $17.12 |
| 4 days before | -11.70% |
| 4 days after | -1.33% |
| On release day | -3.34% |
| Change in period | -12.88% |
| Release date | Feb 24, 2026 |
| Price on release | $21.96 |
| EPS estimate | - |
| EPS actual | $0.0037 |
| Date | Price |
|---|---|
| Feb 18, 2026 | $20.25 |
| Feb 19, 2026 | $19.82 |
| Feb 20, 2026 | $20.43 |
| Feb 23, 2026 | $20.32 |
| Feb 24, 2026 | $21.96 |
| Feb 25, 2026 | $21.21 |
| Feb 26, 2026 | $21.22 |
| Feb 27, 2026 | $20.94 |
| Mar 02, 2026 | $20.07 |
| 4 days before | 8.44% |
| 4 days after | -8.61% |
| On release day | -3.42% |
| Change in period | -0.89% |
Croda International Earnings Call Transcript Summary of Q4 2025
Croda reported solid FY2025 performance with constant-currency sales up 7% to £1.7bn and adjusted PBT up 8% to £276m. Sales momentum was broad-based: Consumer Care +8% (Fragrances & Flavors +15%, Beauty Actives +6) and Life Sciences +8% (Crop Protection +14%). Adjusted operating margin improved to 17.4% (17.6% in H2) driven by volume, positive price/mix trends and early transformation savings, although FX and exceptional/non‑cash charges (notably a £45m impairment at the Lamar lipid site) weighed on reported PBT. Free cash flow improved to £162m, net debt fell to £524m (1.3x EBITDA) and the Board proposed a final dividend of 63p (full-year 111p). Management laid out a clear 2026–2028 framework: targeted organic group growth of 3–6% pa, Life Sciences 4–7% and Consumer Care 3–6%; recurring transformation savings of £100m (targeted by 2028) and a working capital reduction of £50m; adjusted operating margin >20% by 2028 and free cash conversion target >12%. Capital intensity will remain modest (~6% of sales), M&A will be small/discipline-focused, and net debt policy remains 1–2x EBITDA with priority to rebuild the dividend. Management emphasized innovation (co-creation, regionalization of capabilities), supply chain and procurement optimization, SKU rationalization, and digital/AI adoption as drivers of margin recovery and more consistent growth. They placed the new U.S. lipids facility on standby to preserve cash and reallocated capacity across existing sites.
